Early glucocorticoid withdrawal in severe <scp>ANCA</scp> ‐associated vasculitis treated with combination cyclophosphamide and rituximab: a single‐centre case series
Glucocorticoid (GC)-related toxicity remains a major challenge in anti-neutrophil cytoplasm antibody-associated vasculitis (AAV). We report five cases of newly diagnosed severe AAV treated with combination cyclophosphamide and rituximab, with the goal of ceasing GCs within 4 weeks. All patients achieved complete remission, with one relapse during follow-up. All remained GC-free at a median follow-up of 12 months. The regimen was well tolerated despite severe renal impairment. These findings support the feasibility of early GC withdrawal in organ-threatening AAV.
Authors
- Philip A. Clayton (ORCID: https://orcid.org/0000-0001-9190-6753)
- Karthik Venkataraman (ORCID: https://orcid.org/0000-0001-8873-0734)
- Joanna Tieu (ORCID: https://orcid.org/0000-0002-2975-176X)
- Jarrad Hopkins
- Chen Au Peh (ORCID: https://orcid.org/0000-0002-9712-0396)
- John Lau (ORCID: https://orcid.org/0000-0001-9283-6953)
- Tania Salehi (ORCID: https://orcid.org/0000-0002-1278-168X)
Institutions
- Royal Adelaide Hospital (AU)
- The University of Queensland (AU)
- Queen Elizabeth Hospital (AU)
- Women's and Children's Health Network (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1111/imj.70212
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00